

## Trianni, MacroGenics enter into a license agreement

08 December 2018 | News

**Trianni, Inc. is a privately held biotech company specializing in antibody discovery technology. TRIANNI's lead technology, The Trianni Mouse, is a powerful, next-generation platform enabling efficient generation of fully-human monoclonal antibodies.**



Trianni, Inc. and MacroGenics, Inc. has announced that they have entered into a license agreement for The Trianni Mouse, a best-in-class transgenic mouse R&D platform for the discovery of fully-human monoclonal antibodies, to support MacroGenics' discovery programs for monoclonal antibody-based therapeutics for the treatment of cancer.

"With the Trianni Mouse in our discovery toolbox, MacroGenics now has the ability to incorporate fully human antibody sequences into molecules that are based on our Fc optimization and multi-specific DART® and TRIDENT™ platforms, further accelerating our discovery and candidate development processes," said Ezio Bonvini, M.D., Chief Scientific Officer of MacroGenics.

"TRIANNI is very happy that MacroGenics has chosen the TRIANNI discovery platform," said Matthias Wabl, PhD, Chairman, President and CEO of TRIANNI. "We are confident that the cutting-edge genomic design of the TRIANNI discovery platform, which combines the complete human antibody repertoire with wild-type mouse immune responses to any target antigen, will be a great asset for MacroGenics' drug discovery programs."

No financial details were disclosed.

Trianni, Inc. is a privately held biotech company specializing in antibody discovery technology. TRIANNI's lead technology, The Trianni Mouse, is a powerful, next-generation platform enabling efficient generation of fully-human monoclonal antibodies. TRIANNI's transgenic platform leverages a novel approach to design made possible by advances in DNA synthesis and genomic modification technology, making it a best-in-class therapeutic antibody discovery platform. The company is headquartered in San Francisco, CA.

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The company generates its pipeline of product candidates primarily

from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.